Evaluación de la Calidad de Vida en Pacientes con Linfoma no Hodgkin y Cáncer Colo-Rectal en Diferentes Etapas Clínicas Atendidos en el Instituto Mexicano del Seguro Social

• Published in: Value in health 2011-07, Vol.14 (5), p.S130-S132
• Main Authors: Balderas-Peña, Luz-Ma-Adriana, MD, PhD, Sat-Muñoz, Daniel, MD, Contreras-Hernández, Iris, MD, MSc, Solano-Murillo, Pedro, MD, Hernández-Chávez, Guillermo-Allan, MD, MSc, Mariscal-Ramírez, Ignacio, MD, Lomelí-García, Martha, Chemist, Pharm, Díaz-Cortés, Margarita-Arimatea, Eng, Mould-Quevedo, Joaquín-Federico, PhD, Palomares-Chacón, Ulises, Balderas-Peña, César-Adrián, Garcés-Ruiz, Oscar-Miguel, MD, Morgan-Villela, Gilberto, MD, MSc
• Format: Article
• Language: eng ; spa
• Subjects: Internal Medicine
• ISSN: 1098-3015
• DOI: 10.1016/j.jval.2011.05.031

Abstract Introduction In Mexico during 2008, were reported 127,604 new cancer cases, 6,347 of them were colorectal cancer cases and 4,276 Non-Hodgkin Lymphoma (NHL) cases. Objective To Evaluate Health Related Quality of Life in Non-Hodgkin Lymphoma and colorectal cancer cases in different clinical stages, attended in a High Specialty Medical facility at the Instituto Mexicano del Seguro Social, during a 13 month period. Results 162 patients were included, 56.8% (n=92) with NHL and 43.2% (n=70) with colorectal cancer. The scores obtained in the NHL group were: Global health status/QoL: 67.75 (±27.55), physical functioning 69.64 (±29.98), role functioning 71.38 (±33.73), emotional functioning 69.7 (±26.57), cognitive functioning 75.36 (±28.01), social functioning 79.35 (±29.38), fatigue 35.27 (±28.27), nausea and vomiting 13.41 (±21.85), pain 28.08 (±30.25), dyspnea 19.20 (±32.11), insomnia 30.80 (±38.03), appetite lost 26.45 (±36.16), constipation 19.20 (±32.11), diarrhea 12.32 (±26.48), financial difficulties 26.09 (±35.57). In colorectal cancer patients the scores were: Global health status/QoL: 68.21 (±24.46), physical functioning 67.38 (±30.45), role functioning 65.48 (±35.70), emotional functioning 66.43 (±26.84), cognitive functioning 78.57 (±26.49), social functioning 75.24 (±31.05), fatigue 37.78 (±31.62), nausea and vomiting 20.00 (±28.32), pain 37.38 (±34.45), dyspnea 11.90 (±26.64), insomnia 28.09 (±35.73), appetite lost 23.81 (±36.40), constipation 19.05 (±32.88), diarrhea 20.95 (±31.17), financial difficulties 34.76 (±38.67). Conclusions With these basal results is important a follow-up with special attention to the treatment and attendance processes, in patients with this neoplasms and their impact on the quality of life.